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Objective: To describe the use of sedatives and neuromuscular blocking agents (NMBs) and their
impact in outcome in an international cohort of patients receiving mechanical ventilation.
Methods: We analyzed the database of a prospective, multicenter cohort of 5,183 adult patients
who received mechanical ventilation for > 12 h. We considered that a patient received a given
agent when it was administered for at least 3 h in a 24-h period.
Results: A total of 3,540 patients (68%; 95% confidence interval [CI], 67 to 69%) received a
sedative at any time while receiving mechanical ventilation. The median number of days of use
was 3 (interquartile range [IQR], 2 to 6 days). The persistent use of sedative was associated with
more days of mechanical ventilation (median, 4 days [IQR, 2 to 8 days], vs 3 days [IQR, 2 to 4 days]
in patients who did not receive sedatives [p < 0.001]); more weaning days (median, 2 days [IQR,
1 to 3 days], vs 2 days [IQR, 1 to 5 days] in patients who did not receive sedatives [p < 0.001]); and
longer length of stay in the ICU (median, 8 days [IQR, 5 to 15 days], vs 5 days [IQR, 3 to 9 days]
in patients who did not receive sedatives [p < 0.001]). Six hundred eighty-six patients (13%; 95%
CI, 12 to 14%) received an NMB for at least 1 day. The median number of days of use was 2 (IQR,
1 to 4 days). The administration of an NMB was independently related with age, a normal
previous functional status, main reason of mechanical ventilation (patients with ARDS received
more NMBs), and with patient management (patients requiring permissive hypercapnia, prone
position, high level of positive end-expiratory pressure, and high airways pressure).
Conclusions: The use of sedatives is very common, and their use is associated with a longer
duration of mechanical ventilation, weaning time, and stay in the ICU. NMBs are used in 13% of
the patients and are associated with longer duration of mechanical ventilation, weaning time, stay
in the ICU, and higher mortality. (CHEST 2005; 128:496–506)
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Abbreviations: CI  confidence interval; IQR  interquartile range; NMB  neuromuscular blocking agent;
OR  odds ratio; PEEP  positive end-expiratory pressure; SAPS  simplified acute physiology score
S edatives, analgesics, and neuromuscular blockingagents (NMBs) are drugs commonly used in the
ICU, mainly in patients requiring mechanical venti-
lation.1 Sedatives and analgesics are often used to
facilitate patient tolerance of invasive mechanical
ventilation. The goals of sedation/analgesia in this
context include decreasing pain and anxiety, reduc-
ing the stress response, and facilitating nursing
care.2,3 Studies4–7 have suggested that we need to
pay attention to the way we provide sedation/analge-
sia because of the potential impact on patient out-
comes such as length of stay in the ICU, days of
mechanical ventilation, and rate of self-extubation.
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Furthermore, the use of sedatives and NMBs have
being shown to correlate with the subsequent pres-
ence of depression and posttraumatic stress disorder
symptoms8,9 and protracted neuromuscular weak-
ness syndromes.10
The current data related to the pattern of use of
sedatives, analgesics, and NMBs during mechanical
For editorial comment see page 477
ventilation are limited and derived largely from mail
survey reports.11–16 Only a few studies17–19 have
tracked drug use over time, and then for brief
intervals. Recently, Bertolini et al18 reported on
2,932 patients enrolled in a multicentric study in
Italy, and noted that 60% received at least one
sedative during the first week in the ICU. Although
51% of the patients in the study were receiving
mechanical ventilation at the time of admission to
the ICU and 71% received mechanical ventilation at
any time during the ICU stay, it is unclear of the type
of drugs and pattern of administration in patients
receiving mechanical ventilation.
The main objective of this study is to describe the
use of sedatives and NMBs in an international cohort
of patients receiving mechanical ventilation. Fur-
thermore, we want to study their impact on patient
outcomes such as duration of mechanical ventilation,
length of ICU stay, and length of hospital stay. We
analyzed the factors associated with their use and the
association with selected outcomes, such as duration
of mechanical ventilation, weaning, ICU stay, and
mortality.
Materials and Methods
We analyzed the database of a prospective, multicenter, inter-
national cohort of 5,183 adult patients who received mechanical
ventilation for  12 h at 361 ICUs in 20 countries.20 The general
physiologic and clinical characteristics of these patients were
previously described and reported.20 The institutional review
board at each center approved the study protocol. For the
purpose of this study, we collected the following information:
demographic data (age, gender, simplified acute physiology score
[SAPS] II), previous functional status, medical or surgical condi-
tion, date of admission to the ICU, date of initiation of mechan-
ical ventilation, and primary indication for mechanical ventila-
tion: acute on chronic respiratory disease (COPD, asthma,
chronic pulmonary disease other than COPD), neurologic disease
(coma, neuromuscular disease), or acute respiratory failure
(ARDS, postoperative, congestive heart failure, aspiration, pneu-
monia, sepsis, trauma, cardiac arrest), date of starting weaning of
mechanical ventilation, date of extubation, and date and status at
discharge from the ICU.
After starting mechanical ventilation, every day for the first 28
days we recorded the use of sedatives, analgesics, and/or NMBs.
We considered that a patient received one of these drugs when it
was administered for at least 3 h in a 24-h period. The presence
or absence of the following variables were evaluated: (1) patient
management, including mode or level of ventilatory support (full
support defined as ventilation with controlled volume or pres-
sure-controlled modes or when patients received synchronized
intermittent mandatory ventilation but mandatory frequency was
similar to the total respiratory rate; partial support defined as
ventilation with pressure support or synchronized intermittent
mandatory ventilation with mandatory frequency lower than total
respiratory rate; noninvasive ventilation; inverse ratio ventilation;
permissive hypercapnia; prone position; and administration of
inhaled nitric oxide); tidal volume (categorized as  6 mL/kg,
from 6 to 10 mL/kg, and  10 mL/kg); applied positive end-
expiratory pressure (PEEP), categorized as  5 cm H2O, from 5
to 10 cm H2O, and  10 cm H2O; peak pressure  50 cm H2O;
and plateau pressure  35 cm H2O; and (2) complications that
developed over the course of the mechanical ventilation: ARDS,
ventilator-associated pneumonia, sepsis, shock, acute renal fail-
ure, hepatic failure, coagulopathy, metabolic acidosis, respiratory
acidosis and hypoxemia defined as a ratio of Pao2 to fraction of
inspired oxygen  200 mm Hg. The ARDS, ventilator-associated
pneumonia, and sepsis were considered as events only if they
appeared  48 h after mechanical ventilation was started. Each
of these conditions has been previously defined.20 The arterial
blood gases corresponded to the values obtained once daily at
approximately 8 am. The ventilator variables corresponded to the
time that the arterial blood gases were obtained.
Statistical Analysis
Data are expressed as mean (SD), median (interquartile range
[IQR]), or proportions as appropriate. Continuous variables were
compared with Student t test or Mann-Whitney U test if the
distribution was nonparametric. Categorical variables were com-
pared using 2 test or Fisher Exact Test; all p values are
two-sided.
Primary outcome were use of sedatives or NMBs. To estimate
the effects of multiple factors on these outcomes, a logistic
regression analysis was performed using a backward stepwise
selection method. The criterion for entering variables tested in
the model were selected at p  0.10. All variables were analyzed
separately in three groups: variables previous to start mechanical
ventilation (age and SAPS II were dichotomized taking as cut-off
point the value that best correlated with the use of sedatives and
NMBs), variables related with patient management, and compli-
cations appearing during mechanical ventilation. Significant vari-
ables (p  0.05) from each group were entered to construct the
final model.
Linear regression analysis was used to estimate the adjusted
relation between the use of sedatives and NMBs with days of
mechanical ventilation, days of weaning, and length of stay in the
ICU. Similar methods were used to determine the variables
associated to the use of benzodiazepines compared with propofol,
taking as cohorts the patients who only received benzodiazepines
or only propofol.
Results
Use of Sedatives
Of the 5,183 ICU patients admitted during the
study period, 3,540 patients (68%; 95% confidence
interval [CI], 67 to 69%) received a sedative at any
time while receiving mechanical ventilation. For
these patients, the median number of days receiving
a sedative was 3 days (IQR, 2 to 6 days). Figure 1
shows the daily percentage of patients who received
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a sedative according to the duration of ventilatory
support. Since we registered information on sedation
for 28 days, we were able to monitor 28,954 patient-
days of ICU stay (96% of total). In 16,681 days of
mechanical ventilation support, or 58% of the days
for all patients, at least one sedative drug was
administered. Benzodiazepines were administered
for a total of 11,445 patients-days of ventilatory
support, propofol for 3,485 patients-days of ventila-
tory support, and opiates for 10,491 patients-days of
ventilatory support.
Most of the patients who did receive sedatives or
analgesics (67.2%) received a combination of drugs.
The most commonly used combinations were ben-
zodiazepines and opiates (25%), followed by propo-
fol and opiates (6%). Figure 2 shows the daily use of
sedatives based on the duration of mechanical ven-
tilation.
Factors Associated With the Use of Sedatives
The factors associated with sedative use are shown
in Table 1. By multivariate analysis, sedatives were
more likely to be administered to Europeans, men,
patients aged  50 years, and those in whom the
main reason for mechanical ventilation was multiple
trauma. Sedation was also independently related
with the need of full ventilatory support, ventilation
with a tidal volume  6 mL/kg or  10 mL/kg, an
applied PEEP  5 cm H2O or  10 cm H2O, and
the administration of an NMB. Finally, sedation was
more likely to be used in patients in whom acute
sepsis and shock developed over the course of
mechanical ventilation.
Outcomes Associates With the Use of Sedatives
The use of sedative drugs was associated with
more days receiving mechanical ventilation (median,
4 days [IQR, 2 to 8 days], vs 3 days [IQR, 2 to 4 days]
in patients who did not receive sedatives
[p  0.001]); more weaning days (median, 2 days
[IQR, 1 to 5 days], vs 2 days [IQR, 1 to 3 days] in
patients who did not receive sedatives [p  0.001]);
and longer length of stay in the ICU (median, 8 days
[IQR, 5 to 15 days], vs 5 days [IQR, 3 to 9 days] in
patients who did not receive sedatives [p  0.001]).
After adjusting for other variables, the use of seda-
tives was independently related with these outcomes
(p  0.001). Sedated patients had a higher mortality
(33% vs 26.5%), however, the use of sedatives was
not independently associated with mortality (odds
ratio [OR], 0.89; 95% CI, 0.75 to 1.05; p  0.17)
Use of NMBs
Six hundred eighty-six patients (13%; 95% CI, 12 to
14%) received an NMB during the study period for at
least 1 day. The median number of days of use of an
NMB was 2 (IQR, 1 to 4 days). An NMB was admin-
istered in 2,271 days of mechanical ventilation (8% of
total days of ventilatory support). Figure 3 shows the
Figure 1. Daily use of sedatives drugs according to duration of mechanical ventilation.
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daily percentage of patients receiving an NMB grouped
according to the duration of mechanical ventilation.
Factors Associated With the Use of NMBs
Table 2 shows the variables associated with the daily
use of NMBs. The administration of an NMB was
independently related to age (more likely to be used in
patients  50 years old); gender (more common in
males); a normal previous functional status; main rea-
son of mechanical ventilation (patients with ARDS
received more NMBs, while patients with coma, neu-
romuscular disease, and postoperative respiratory fail-
ure were less likely to receive these agents); with
management strategy (patients requiring full ventila-
Figure 2. Daily use of benzodiacepines and propofol according to duration of mechanical ventilation.
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tory support, permissive hypercapnia, prone position,
high level of PEEP, and high airways pressure were
more likely to receive an NMB); and complications
during mechanical ventilation (ventilator-associated
pneumonia and respiratory acidosis) were the events
related with the use of NMBs.
Table 1—Variables Associated With Sedative Use by Univariate and Multivariate Analysis
Variables No. Use of Sedatives, No. (%)
Univariate Analysis Multivariate Analysis
OR 95% CI OR 95% CI
Geographic area
Latin America 1,222 684 (56) 1 1
United States-Canada 1,455 987 (68) 1.65 1.42–1.94 3.60 2.77–4.67
Europe 2,506 1,869 (75) 2.30 1.99–2.67 4.97 3.75–6.58
Age, yr
 50 3,675 2,449 (66) 1 1
50 1,508 1,085 (72) 1.30 1.13–1.45 1.30 1.04–1.64
SAPS II score
 50 points 1,759 1,151 (65) 1
50 points 3,424 2,389 (67) 1.22 1.07–1.37
Gender
Female 1,985 1,267 (64) 1 1
Male 3,198 2,273 (71) 1.39 1.23–1.56 1.31 1.08–1.61
Problem
Medical 3,428 2,253 (66) 1 1
Surgical 1,755 1,287 (73) 1.43 1.26–1.63 2.02 1.62–2.51
Previous functional status
Limited activity 2,016 1,326 (66) 1
Normal 3,167 2,214 (70) 1.20 1.07–1.37
COPD 522 336 (64) 0.82 0.68–099
Coma 864 472 (55) 0.49 0.42–0.57 0.47 0.36–0.62
Neuromuscular disease 94 48 (51) 0.48 0.32–0.72
ARDS 231 201 (87) 3.24 2.19–4.78
Postoperative acute respiratory failure 1,080 764 (71) 1.16 1.00–1.33
Pneumonia 721 530 (73) 1.34 1.12–1.60
Sepsis 458 375 (82) 2.23 1.74–2.85
Trauma 407 343 (84) 2.65 2.01–3.48 1.58 1.04–2.39
Cardiac arrest 100 54 (54) 0.54 0.36–0.80
Full ventilatory support 4,248 3,113 (73) 3.26 2.82–3.77 63.36 43.21–92.92
Partial ventilatory support 1,677 542 (32) 0.08 0.07–0.09 0.008 0.006–0.012
Tidal volume, mL/kg
6–10 2,652 1,769 (67) 1 1
 10 1,920 1,323 (69) 1.11 0.97–1.25 1.34 1.09–1.65
 6 571 498 (71) 1.25 1.02–1.52 1.49 1.07–2.08
Level of applied PEEP, cm H2O
5–10 1,258 623 (49) 1 1
 5 2,298 1,495 (65) 1.89 1.65–2.18 2.86 2.27–3.60
 10 745 674 (90) 9.68 7.39–12.65 5.99 4.08–8.78
Noninvasive ventilation 247 74 (30) 0.18 0.14–0.24 0.22 0.14–0.35
Inverse-relation ventilation 95 88 (93) 5.96 2.75–12.89
Permissive hypercapnia 94 89 (95) 8.45 3.43–20.84
Prone position 72 70 (97) 16.55 4.05–67.58
Nitric oxide inhaled 54 54 (100)
Peak pressure 50 cm H2O 207 172 (83) 2.35 1.62–3.39
Plateau pressure 35 cm of water 143 128 (89) 4.07 2.38–6.97
Use of NMBs 686 670 (98) 23.74 14.40–39.12 17.81 9.23–34.35
Barotrauma 140 116 (83) 2.28 1.47–3.56
ARDS during mechanical ventilation 375 345 (92) 5.81 3.40–8.47 2.86 1.64–4.98
Ventilator-associated pneumonia 814 641 (79) 1.88 1.57–2.25
Sepsis during mechanical ventilation 724 626 (86) 3.39 2.71–4.23 2.47 1.74–3.52
Shock 1,204 980 (81) 2.42 2.07–2.84 1.36 1.03–1.79
Acute renal failure 1,029 819 (80) 2.05 1.74–2.42
Hepatic failure 340 268 (79) 1.79 1.37–2.33
Coagulopathy 580 482 (83) 2.48 1.98–3.11
Metabolic acidosis 428 330 (77) 1.62 1.28–2.05
Respiratory acidosis 545 429 (79) 1.81 1.46–2.25
500 Clinical Investigations in Critical Care
Downloaded From: http://journal.publications.chestnet.org/ by a Hospital Amadora Sintra User  on 08/14/2012
Outcomes Associated With the Use of NMBs
The use of NMBs was associated with a longer
duration of mechanical ventilation (median, 7 days
[IQR, 4 to 13 days], vs 3 days [IQR, 2 to 6;
p  0.001]); duration of weaning (median, 3 days
[IQR, 1 to 6 days], vs 3 days [IQR, 1 to 4; p  0,001];
and stay in the ICU (median, 10 days [IQR, 6 to 19
days], vs 7 days [IQR, 4 to 12 days; p  0.001]). The
mortality of patients who received NMBs was 50%
(95% CI, 46 to 55%), and the use was independently
related with mortality in the ICU (OR, 1.39; 95% CI,
1.08 to 1.79) [p  0.001].
Discussion
The main findings of this prospective, interna-
tional, multicentric, observational study are as fol-
lows: (1) 68% (3,540 of 5183 patients receiving
mechanical ventilation) received a sedative at any
time while receiving mechanical ventilation; (2) the
persistent use of sedatives was associated with more
days of mechanical ventilation, more weaning days,
and longer length of stay in the ICU; (3) NMBs were
used in 13% (686 of 5,183 patients); and (4) patients
requiring NMB has a longer duration of mechanical
ventilation, weaning time, ICU stay, and higher
mortality.
The use of sedatives and analgesics are very
common in the ICU; however, the frequency of use
of these medications is not well known. Bertolini et
al18 found that 60% of 2,932 patients admitted to 128
adult, general ICUs received a sedative or analgesic.
The most common sedatives were propofol (40%)
and diazepam (34%); the most common analgesics
were fentanyl (36%) and morphine (22%). In their
patients, the prevalence of sedation tends to de-
crease linearly overtime. Unfortunately no data of
outcomes were described in this study. Similarly to
Bertolini et al,18 we found that 68% of our patients
received a sedative at any moment during the ICU
stay. Most of the patients received the sedative for a
short period of time, and two thirds (67%) received
a combination of drugs, more commonly benzodiaz-
epines and opiates. Patients who received sedatives
had longer time on mechanical ventilation, a longer
weaning period, and a longer ICU stay.
The usage of NMBs is less known than the use of
sedatives.11,12,21–23 Small, single-institution, prospec-
tive studies1,22,23 suggest that the rates vary between
3.4% and 15.5%. Watling et al17 reported a survey of
the use of sedatives, analgesics, and NMB in the
United States. After the survey was completed, the
study participants were asked to collect drug admin-
istration information for 5 consecutive days on all
patients in the ICUs during the study period. Nine
percent of their patients received an NMB. Unfor-
tunately, the authors17 did not offer information
regarding the patient characteristics or concomitant
therapy. Murray et al24 did a retrospective audit of
the use of NMBs in a tertiary care medical center for
a 3-month period, showing that NMB use in the ICU
Figure 3. Daily use of NMBs according to duration of mechanical ventilation.
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was 1.4%, mainly in patients admitted with acute
respiratory failure as a reason for mechanical venti-
lation (9%). In our study, 13% of the patients
received an NMB during the ICU stay. The use was
short (median of 2 days) and was likely to be
associated with severe respiratory failure, as sug-
gested by the factors associated with their use.
Contrary to the use of sedatives, there was an
association with a higher mortality on univariate and
multivariate analysis. We speculate that the use of an
NMB is usually a final option in the management of
severely ill patients, and the frequency of use is
reduced when patients are treated following clinical
practice guidelines.25
The major limitation of our study is that it is an
observational study related to the use of mechanical
ventilation and was not specifically design to study
the usage of sedatives or NMBs. Therefore, there is
Table 2—Variables Associated With NMB Use by Univariate and Multivariate Analysis
Variables No. Use of NMBs, No. (%)
Univariate Analysis Multivariate Analysis
OR 95% CI OR 95% CI
Geographic area
United States-Canada 1,455 167 (11.5) 1
Europe 2,506 319 (13) 1.12 0.92–1.37
Latin-America 1,222 200 (16) 1.51 1.21–1.88
Age, yr
 50 3,675 372 (10) 1 1
50 1,508 313 (21) 2.32 1.98–2.74 2.28 1.85–2.80
Gender
Female 1,985 203 (10) 1 1
Male 3,198 483 (15) 1.56 1.31–1.86 1.57 1.27–1.94
Previous functional status
Limited activity 2,016 202 (10) 1 1
Normal 3,167 484 (15) 1.62 1.36–1.93 1.53 1.23–1.92
COPD 522 40 (8) 0.51 0.37–0.72
Asthma 79 19 (24) 2.10 1.01–3.55
Coma 864 87 (10) 0.69 0.54–0.88 0.61 0.45–0.83
Neuromuscular disease 94 4 (4) 0.29 0.10–0.78 0.22 0.06–0.87
ARDS 231 87 (38) 4.39 3.32–5.80 2.01 1.43–2.83
Postoperative acute respiratory failure 1,080 98 (9) 0.60 0.58–0.75 0.65 0.49–0.86
Congestive heart failure 539 47 (9) 0.60 0.44–0.82
Aspiration 129 27 (21) 1.76 1.14–2.72
Pneumonia 721 144 (20) 1.80 1.47–2.21
Sepsis 458 83 (18) 1.51 1.17–1.95
Trauma 407 94 (23) 2.12 1.66–2.71
Full ventilatory support 4,338 662 (15) 6.16 4.07–9.32 3.68 2.38–5.70
Inverse-relation ventilation 89 43 (48) 6.47 4.23–9.88
Permissive hypercapnia 88 54 (61) 11.22 7.24–17.36 4.49 2.53–7.95
Prone position 66 42 (64) 12.15 7.31–20.20 4.36 2.33–8.12
Nitric oxide inhaled 47 32 (68) 14.62 7.87–27.14
Level of applied PEEP, cm H2O
 5 3,112 218 (7) 1 1
5–10 757 125 (16) 2.62 2.07–3.32 1.94 1.50–2.50
 10 737 239 (32) 6.37 5.18–7.83 3.06 2.39–5.70
Tidal volume, mL/kg
6–10 2,466 272 (11) 1
 10 2,076 307 (15) 1.40 1.17–1.67
 6 641 107 (17) 1.61 1.27–2.06
Peak pressure  50 cm H2O 291 93 (32) 3.40 2.62–4.42 1.46 1.04–2.06
Plateau pressure  35 cm H2O 186 78 (42) 5.21 3.85–7.06 2.19 1.45–3.22
Barotrauma 143 31 (22) 1.85 1.23–2.78
ARDS during mechanical ventilation 413 123 (30) 3.17 2.52–3.98
Ventilator-associated pneumonia 855 131 (15) 1.23 1.00–1.51 1.48 1.14–1.91
Sepsis during mechanical ventilation 742 154 (21) 1.92 1.58–2.35
Shock 1,211 224 (18) 1.72 1.45–2.05
Acute renal failure 1,022 176 (17) 1.49 1.23–1.79
Coagulopathy 581 107 (18) 1.57 1.25–1.97
Metabolic acidosis 448 76 (17) 1.38 1.06–1.79
Respiratory acidosis 554 144 (26) 2.65 2.15–3.26 1.40 1.06–1.87
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relevant information that we do not have available,
such as the indications for sedation and/or NMBs, or
the use of protocols for sedation and/or NMB in the
participating ICUs. There are data in the literature
that suggest that sedation protocols can have a
significant impact on outcome.20 However, in a
survey by Rhoney and Murry,26 only 33% of the 474
respondent reported the use of protocols for seda-
tion in their ICUs, and 47% reported the use of
protocols for NMBs.
Another limitation is that we do not have any
information concerning the route of drug adminis-
tration (ie, continuous IV infusion or intermittent
bolus), doses, ways to monitor the depth of sedation,
or level of neuromuscular blockade. Finally, we did
not obtain information related to specific drugs
sedatives and/or NMBs. Despite these limitations,
the data presented in this article provide a significant
insight into the patterns of usage of these drugs and
their potential impact on patient outcome.
In conclusion, this study advances the knowledge
of this important aspect of the care of the critically ill
by describing patient characteristics and outcomes in
those who receive sedatives and NMBs. This study
has shown that the persistent use of sedatives is
associated with longer duration of mechanical venti-
lation, more weaning days and, consequently, a
longer length of stay in the ICU. Furthermore,
patients who receive NMBs not only have a longer
duration of ICU stay, but also increased mortality.
We need to recognize that in order to provide
patient comfort and facilitate the tolerability of
mechanical ventilation, these medications need to be
used, and in many circumstances the clinician has no
alternatives. We believe that a prospective study
specifically designed to address the issues identified
in this study should be conducted in order to pro-
spective verify our findings.
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Guidi (Hospital Italiano Garibaldi, Rosario); L. Huespe Gardel
(Hospital Escuela Jose´ F. de San Martı´n, Corrientes); C. Irraza´-
bal (Hospital de Clı´nicas Jose´ de San Martı´n, Buenos Aires); O.
Lo´pez (Sanatorio Santa Isabel, Buenos Aires); G. Menga (Hos-
pital Marı´a Ferrer, Buenos Aires); O. Otero (Centro Oncolo´gico
de Excelencia, Gonnet); F. Pa´lizas (Clı´nica Bazterrica, Buenos
Aires); P. Pardo (Sanatorio de la Trinidad, Buenos Aires); C.
Plaza (Sanatorio Julio Me´ndez, Buenos Aires); G. Raimondi
(FLENI, Buenos Aires); A. Raimondi (Sanatorio Mater Dei,
Buenos Aires); E. Romero (Hospital Privado Centro Me´dico,
Co´rdoba); L. de Rosa (Sanatorio Quintar, San Salvador); C. Sa´ez
(Sanatorio Brita´nico, Rosario); A. Sarsino (Hospital Juan A.
Ferna´ndez, Buenos Aires); P. Schoon (Hospital Prof. Luis
Gu¨emes, Haedo); C. Sola (Hospital Jose´ Penna, Bahı´a Blanca); C.
Sto¨ltzing (Hospital Guillermo Rawson, San Juan); J. Taccone
(Instituto Alfredo Lanari, Buenos Aires); C. Tolosa (Hospital
Co´rdoba, Co´rdoba); M. Torreno (Sanatorio Modelo Quilmes,
Quilmes); E. Turchetto (Hospital Privado de la Comunidad, Mar
de Plata); R. Valenti (CEMIC, Buenos Aires); R. Vargas (Poli-
clı´nico Neuquen, Neuquen); L. Vasta (Sanatorio San Patricio,
Buenos Aires); L. Va´zquez (Hospital Espan˜ol, Godoy Cruz);
Vetere (Hospital Israelita Ezrah, Buenos Aires); F. Villarejo
(Hospital Prof. Alejandro Posadas, Haedo); N. Wainsztein (Hos-
pital Privado Fundacio´n Favaloro, Buenos Aires); O. Yunk (Hos-
pital Espan˜ol, Buenos Aires); G. Zabert (Clı´nica Pasteur, Neu-
quen).
Bolivia: Coordinator: F. Sandi Lora. L. Moya (Hospital Juan
XXIII, La Paz); E. Salazar (Hospital Japone´s, Santa Cruz); J.C.
Zapata (Hospital Obrero, La Paz).
Brazil: Coordinator: C.M. David. S.M. Ajeje Lobo (Hosp. de
Base de Sa˜o Jose´ do Rio Preto, Sa˜o Jose´ do Rio Preto); A.B. de
Almeida (Hospital das Clı´nicas da Univers. Federal, Uberlandia);
M.A. Braga (Hospital Biocor, Belo Horizonte); I. Buselato Chen
(Hospital Nossa Senhora das Grac¸as, Curitiba); M. Chaves
Craveiro de Melo (Hospital Sa˜o Lucas, Belo Horizonte); RN.
Darwich (Hospital Prontocor, Belo Horizonte); C.M. David
(Hospital Clementino Fraga Filho, Rio de Janeiro); R. Goldstein
Alheira Rocha. (Hospital Samaritano, Sa˜o Paulo); R. de Macedo
Bosco (Hospital Madre Teresa, Belo Horizonte); J.M. Nogueira
(Hospital Universitario Sa˜o Jose´. Belo Horizonte); E. Oliveira
(Hospital Vera Cruz, Belo Horizonte); S.F. Pinto (Casa de Sau´de
Sa˜o Jose´, Campo Grande); S.F. Pinto (Santa Casa de Campo
Grande, Campo Grande); S.F. Pinto (Univ. Fed. Mato Grosso do
Sul, Campo Grande); J.L. da Rocha Paranhos (Santa Casa de
Misericordia, Sa˜o Joa˜o del Rei); L.R. de Siqueira Musolino
(Irmandade da Santa Casa de Misericordia, Sa˜o Paulo).
Canada: Coordinator: T.E. Stewart. R. Fowler (Wellesley-
Central Hospital, Toronto). J. Granton (Toronto Hospital Gen-
eral Division, Toronto); J. Granton (Toronto Hospital Western
Division, Toronto); R. Hodder (Ottawa Civic Hospital, Ottawa);
B. Kashin (Peel Memorial Hospital, Brampton-Ontario); S. Lap-
insky (Mount Sinai Hospital, Toronto); D. Mazer (St Michael’s
Hospital, Toronto); R. McLean (Sunnybrook Health Sciences
Centre, Toronto); T. Rogovein (St Joeseph’s Health Centre,
Toronto).
Chile: Coordinator: L. Soto. G. Buguedo (Hospital Pontificia
Universidad Cato´lica, Santiago); P. Herna´ndez (Instituto Nacio-
nal del To´rax, Santiago); C. Ortega (Hospital Regional Concep-
cio´n, Concepcio´n); L. Soto (Hospital de Coquimbo, Coquimbo);
L. Scho¨lz (Hospital de Osorno, Osorno).
Colombia: Coordinator: M. Gonza´lez. H. Atehortua (Clı´nica
Sta. Marı´a. Centro Cardiovascular, Medellı´n); C. Cadavid (Hos-
pital Pablo Tobo´n Uribe, Medellı´n); D. Camargo (Hospital
Universitario, Barranquilla); C. Duen˜as (Hospital Universitario,
Cartagena); A. Guerra (Hospital General, Medellı´n); M. Grana-
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dos (Fundacio´n Valle de Lilly, Cali); R. Panesso (Clı´nica Las
Ame´ricas, Medellı´n); M.A. Perafa´n (Clı´nica Shaio, Bogota´).
Ecuador: Coordinator: J. Raad. B. Guevara (Hospital Carlos
Andrade, Quito); J. Molina (Hospital Militar, Quito); J. Raad
(Hospital Militar, Quito).
France: Coordinator: L. Brochard. P. Andrivet (Centre
Me´dico-Chirurgical de Bligny, Bris-sous-Forges); D. Annane
(Hoˆpital Raymond Poincare´, Garches); C. Arich (CHU de
Nimes, Nimes); F. Baud (Hoˆpital Lariboisie`re, Paris); F. Bellen-
fant (Hoˆpital Cochin, Paris); R. Boiteau (Hoˆpital Louise Michel,
Evry); F. Brivet (Hoˆpital A. Be´cle`re, Clamart); M. Canonne
(C.H.G. Les Feugrais, Elbeuf); J.P. Cardinaud (Hoˆpital Pelle-
grin-Tripode, Bourdeaux); E. Cle´menti (Centre Hosp. Dept, La
Roche/Yon); P. Charbonneau (C.H.U. Coˆte de Nacre, Caen);
J. Chastre (Hoˆpital Bichat, Paris); R. Chauveau (C.H. Andre´
Gre´goire, Montreuil-Ss-Bois); C. Chopin (CHRU - Hoˆpital B,
Lille); J.M. Descamps (Centre Hospitalier de Niort, Niort); D.
Dreyfuss (Hoˆpital Louis Mourier, Colombes); J.P. Faller (C.
Hosp. de Belfort, Belfort); F. Fraisse (Hoˆpital Delafontaine,
Saint-Denis); C. Girault (Hoˆpital Charles Nicolle, Rouen); C.
Gue´rin (Hoˆpital Croix Rousse, Lyon); E. Guerot (Hoˆpital Bouci-
caut, Paris); F. Hilpert (Hoˆpital Ballanger, Aulnay-sous-Bois); L.
Holzapfel (Centre Hospitalier, Bourg-en-Bresse); F. Jardin (Hoˆ-
pital Ambroise Pare´, Boulogne Vignancourt); O. Jonquet (Hoˆpital
Gui de Chauliac, Montpellier); E. L’Her (CHU de la Cavale
Blanche, Brest); Y. Lefort (Hoˆpital Henri Mondor, Creteil); O.
Leroy (Centre Hospitalier, Tourcoing); Y. Le Tulzo (CHU
Pontchaillon, Rennes); Ch. Mayaud (Hoˆpital Tenon, Paris); H.
Mentec (Hoˆpital Victor Dupouy, Argenteuil); A. Mercat Hoˆpital
Bice´tre, Kremlin-Bicetre); B. Misset (Hoˆpital Saint-Joseph, Par-
is); P. Moine (Hoˆpital Biceˆtre, Bicetre); G. Nitemberg (IGR,
Villejuif); L. Papazian (Hoˆpital Sainte Marguerite, Marseille); A.
Rabbat (Hoˆpital Hoˆtel-Dieu, Paris); T. Similowski (Hoˆpital Pitie´
Salpe´trie`re, Paris); L. Soufir (Hoˆpital Saint-Louis, Paris); D.
Tardy (Hoˆpital Saint-Camille, Bry-sur-Marne); F. Thaler (CM
Chirurgical Foch, Suresnes); B. Vallet (Centre Hospitalier Univ.,
Lille); D. Villers (C.H.U. Nantes, Nantes); M. Wysocki (Institut
Mutualiste Montsouris, Paris); J.F. Zazzo (Hoˆpital A. Be´cle`re,
Clamart).
Greece: Coordinator: D. Matamis. D. Georgopoulus (Herak-
lion University Hospital, Heraklion); M. Gianakou (Ahepa Uni-
versity Hospital, Thessaloniki); D. Lagonidis (Papanikolaou Hos-
pital, Thessaloniki); G. Nakos (Ioanina University Hospital,
Ioanina); K. Stavrakaki (Evangelismos Hospital, Athens); G.
Thomopoulus (Laikon Hospital, Athens).
Ireland: Coordinator: G. Fitzpatrick. M. Donnelly (Adelaide
and Meath Hospital, Dublin); J. Moriarty (St. James Hospital,
Dublin); B. O’Sullivan (Waterford Regional Hospital, Water-
ford); G. Shorten (Cork University Hospital, Cork).
Italy: Coordinator: P. Pelosi. Cositi (Pol. Umberto I, Roma); G.
Iapichino (Hospital S. Paolo, Milano); P. Pelosi (Policlı´nico,
Milano); A. Pesenti (Dsp. S. Gerardo, Monza).
Mexico: Coordinator: J. Elizalde. F. Aguilera Almaza´n (Hospi-
tal General Regional N° 1, Chihuahua); M. Benitez Cortazar
(Hospital Universitario de Puebla, Puebla); R. Carrillo Speare
(Hospital PEMEX Sur, Me´xico DF); R. Castan˜o (Hospital de
Cardiologı´a del CMN, Me´xico DF); R. Corral (Hospital Excel.
Tijuana, Baja California); D.M. D’Ector Lira (Hospital Metro-
politano, Me´xico DF); G. Dı´az Polanco (Hospital de Traumato-
logı´a Magdalena de las Salinas, Me´xico DF); J.J. Elizalde (Hos-
pital ABC, Me´xico DF); R. Envila Fisher (Hospital Morelos,
Chihuahua); R. Envila Fisher (Hospital Clı´nica del Parque,
Chihuahua); G. Franco G. (Hospital General de Me´xico, Me´xico
DF); P. Garcı´a Balbuena (Hospital General “Fernando Quiroz,”
Me´xico DF); O. Gayoso Cruz (Hospital Regional “Adolfo Lo´pez
Mateos,” Me´xico DF); L. Green (Instituto Nacional de Cancero-
logı´a, Me´xico DF); J.O. Herrera Hoyos (Centro Me´dico Las
Ame´ricas, Me´rida); J. Hinojosa (Hospital Angel Lean˜o, Guadala-
jara); J. Huerta (Clı´nica Londres, Me´xico DF); V.A. Jua´rez
(Hospital Santelena, Me´xico DF); M. Loera (Hospital General
Durango, Durango); C. Lo´pez Alzate (Clı´nica del Mar, Mazat-
la´n); E. Lo´pez Mora (Instituto Nacional de Cardiologı´a, Me´xico
DF); S. Martı´nez Cano (Hospital Hidalgo Aguascalientes, Aguas-
calientes); R. Mendez Reyes (Hospital Regional 1° de Octubre,
Me´xico DF); M. Mendoza (Hospital General de la Villa, Me´xico
DF); O. Narva´ez Porras (Instituto Nacional de Enfermedades
Respiratorias, Me´xico DF); E. Ortiz (Hospital General Irapuata,
Guanajuato); A. Padua (Hospital General Torreo´n, Coahuila); M.
Poblano (Hospital Jua´rez, Me´xico DF); V. Pureco Reyes (Hos-
pital Regional “20 de Noviembre,” Me´xico DF); W. Querevalum
(Hospital Central Cruz Mexicana, Me´xico DF); A. Quesada
(Hospital Ntra. Sra. de la Salud, San Luis Potosı´); A. Ramı´rez
Rivera (Hospital de Enfermedades Cardiovasculares y del To´rax.
IMSS, Monterrey); A. Tamariz (Hospital Clı´nica del Centro,
Chihuahua); A. Tamariz (Hospital Central Universitario, Chihua-
hua); A. Vargas (Hospital General de Pachuca, Pachuca); C.
Va´zquez (Hospital General Celaya, Guanajuato).
Peru: Coordinator: A. M. Montan˜ez. M. Contardo (Edgardo
Rebagliati Martins - UCI 7°B, Lima); E. Durand (Guillermo
Almenara Irigoyen–IPPS, Lima); M. Manrique (Hospital “Jose
Casimiro Ulloa,” Lima); J.C. Meza (Centro Me´dico Naval, Lima);
J. Mun˜oz (Edgardo Rebagliati Martins - UCI 2°C, Lima); J.
Pacheco (Hospital del Apoyo “Marı´a Auxiliadora,” Lima); C.
Salcedo (Hosp. Nacional “Daniel Alcides Carrio´n,” Lima); J. Silva
(Hospital Central FAP, Lima); C. Torres (Hospital Nacional
“Arzobispo Loayza,” Lima).
Portugal: Coordinator: J. Pimentel. P. Amaro (Centro Hospi-
talario de Gaia, Gaia); F. Faria (Instituto Portugue´s de Oncologı´a,
Porto); P. Freitas (Hospital Fernando da Fonseca, Amadora-
Sintra); P. Martins (Hospital Universidade, Coimbra); E. Sabino
(Hospital Garcı´a de Orta, Almada); J. Salcher (Hospital de San
Jose´. UUM, Lisboa); E. Silva (Hospital Senhora do Desterro,
Lisboa).
Spain: Coordinators: A. Esteban, F. Frutos-Vivar. J.M. Allegre
(Hospital Nuestra Sen˜ora del Rosell, Cartagena), S. Alonso
(Hospital Joan XXIII, Tarragona), A. Alvarez Ruiz (Hospital
General Rio Carrio´n, Palencia), B. Alvarez Sa´nchez (Hospital
General, Alicante), MT Antuna (Hospital de Cabuen˜es, Gijo´n),
J.M. An˜o´n (Hospital Virgen de la Luz, Cuenca), P. Arribas
(Hospital 12 de Octubre, Madrid), A. Ayensa (Hospital Virgen de
la Salud, Toledo), A. Azca´rate (Hospital Nuestra Sen˜ora de
Aranzazu, Donostia), J. Blanco (Hospital del Rı´o Hortega, Vall-
adolid), G.M. Besso (Hospital Carlos Haya, Ma´laga), L. Cabre´
(Hospital de Barcelona, Barcelona), F. Carrizosa (Hospital Gen-
eral, Je´rez de la Frontera), J. Castan˜eda (Hospital Clı´nico,
Valladolid), R. de Celis (Hospital de Galdakao, Galdakao), J.A.
Conesa (Hospital Clı´nico Universitario San Carlos, Madrid), J.
Diarte (Complejo Hospitalario, Ciudad Real), A. Dı´az Lamas
(Complejo Hospitalario Cristal Pin˜or, Orense), R. Ferna´ndez
(Consorci Hospitalari del Parc Taulı´, Sabadell), M. Ferrer (Hos-
pital Clinic i Provincial, Barcelona), D. Fontaneda (Hospital
Virgen Blanca, Leo´n), P. Galdo´s (Hospital General, Mo´stoles), A.
Garcı´a Jime´nez (Hospital Arquitecto Marcide, El Ferrol), J.
Garcı´a Pardo (Hospital Juan Canalejo, La Corun˜a), J. Gener
(Hospital Germans Trias i Pujol, Badalona), J.A. Go´mez Rubı´
(Hospital Virgen de la Arrixaca, Murcia), G. Gonza´lez Dı´az
(Hospital Morales Meseguer, Murcia), S. Gonza´lez Prado (Hos-
pital Josep Trueta, Girona), C. Homs (Hospital General San
Jorge, Huesca), J. Iban˜ez (Hospital Son Dureta, Palma de
Mallorca), F. Jara (Hospital Mutua, Terrassa), M. Leo´n (Hospital
Arnau de Vilanova, Lleida), A. Lloria (Complejo Hospitalario
Rebullo´n, Pontevedra), J. Lo´pez Dı´az (Hospital La Paz, Madrid),
MS¸R. Lorenzo (Complejo Hospitalario Materno-Infantil, Las
Palmas de Gran Canaria), S. Macı´as (Hospital General, Segovia),
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J.A. Maldonado (Hospital de la Serranı´a, Ronda), J. Maynar
(Hospital Santiago Apostol, Vitoria), A. Moreno (Complejo Hos-
pitalario de San Milla´n-San Pedro, Logron˜o), A. Mota (Hospital
General Universitario, Elche), T. Mut (Hospital General, Castel-
lo´n), M. Nolla (Hospital General de Catalun˜a, Sant Cugat del
Valle´s), F. Ortega (Hospital Universitario de Valme, Sevilla), R.
de Pablo (Hospital Prı´ncipe de Asturias, Alcala´ de Henares), E.
Palazo´n (Hospital General Universitario, Murcia), V. Parra (Hos-
pital de Sagunto, Sagunto), A. Peral (Hospital Gregorio Maran˜o´n,
Madrid), J.C. Portela (Complejo Hospitalario Xeral-Calde,
Lugo), A. Ramı´rez (Hospital Nuestra Sen˜ora de Sonsoles, Avila),
J.A. Ramos (Hospital de Poniente, El Ejido), P. Revuelta (Hos-
pital Universitario de Canarias, La Laguna), M. Rey (Complejo
Hospitalario, Santiago de Compostela), J.J. Rodrigo (Hospital
Nuestra Sen˜ora del Pino, Las Palmas de Gran Canaria), J.C.
Rodrı´guez Borregan (Hospital Marque´s de Valdecilla, San-
tander), J.A. Rodrı´guez Sarria (Hospital General, Elda), A. Rubio
(Hospital Ramo´n y Cajal, Madrid), S. Ruiz Navarro (Hospital
General Ciudad de Jaen, Jaen), V. Sagredo (Hospital Virgen de la
Vega, Salamanca), P. Saura (Centre Hospitalari, Manresa), M.J.
Serralta (Hospital Universitario de San Juan, Alicante), J.F.
Solsona (Hospital del Mar, Barcelona), F. Sua´rez Sipmann
(Fundacio´n Jime´nez Dı´az, Madrid), F. Taboada (Hospital Gen-
eral de Asturias, Oviedo), S. Temprano (Hospital Severo Ochoa,
Legane´s), J.P. Tirapu (Hospital de Navarra, Pamplona), MS¸V. de
la Torre (Hospital Universitario Virgen de la Victoria, Ma´laga), P.
Ugarte (Hospital Marque´s de Valdecilla, Santander), M. Valledor
(Hospital de San Agustı´n, Avile´s), I. Vallverdu´ (Hospital de la
Santa Creu i Sant Pau, Barcelona), C. Vaquerizo (Hospital 12 de
Octubre, Madrid), A. Vin˜uales (Hospital Lluis Alcanyis, Xa´tiva).
Tunisia: Coordinator: F. Abroug. A. Bchiz (Hospital F. Bached,
Sousse); J. Ben Khelil (Hospital A. Mami, Ariana); S. Bern Lakhal
(Hospital Rabta, Tunis); B. Bouhaja (Hospital Mongi Slim, La
Marsa); H. Chelly (Hospital Fattouma Bourguiba, Sfax); S. El
Atrous (Hospital Fattouma Bourguiba, Monastir); S. Ghedira
(Hospital Charles Nicolle, Tunis); H. Thabet (CAMUR. Tunis).
United Kingdom: Coordinator: P. Nightingale. O. Akinpelu
(Chorley & District Hospital, Chorley); D. Bardgett (Maccles-
field District General Hospital, Macclesfield); A. Batchelor
(Royal Victoria Infirmary, Newcastle on Tyne); R. Beale (Guy’s
Hospital, London); K. Burchett (Queen Elizabeth Hospital,
King’s Lynn); N. Coleman (North Staffordshire Royal Infirmary,
Stoke on Trent); A. Conn (Wansbeck General Hospital, Ashing-
ton); D. Edbrooke (Royal Hallamshire Hospital, Sheffield); N.
Fergusson (Countess of Chester Hospital, Chester); I. Grant
(Rotherham District Hospital, Rotherham); K. Gunning (Adden-
brooke’s Hospital, Cambridge); J. Harper (Royal Liverpool Uni-
versity Hospital, Liverpool); D. Higgins (Southend Hospital,
Westcliffe-on-Sea); D. Jayson (Southport & Formby General
Hospital, Southport); R. Loveland (Wexham Park Hospital,
Slough); L. Lynch (Birmingham Heartlands Hospital, Birming-
ham); I. Macartney (North Manchester General Hospital,
Manchester); E. Major (Morriston Hospital, Swansea); S. Mous-
dale (Blackbum Royal Infimary, Blackburn); N. Soni (Chelsea
and Westminster Hospital, London); D. Watson (Walsgrave
Hospital, Walsgrave).
Uruguay: Coordinator: C. Rodrigo. H. Bagnulo (Maciel, Mon-
tevideo); C. Rodrigo (Asociacio´n Espan˜ola Primera, Montev-
ideo); M. Rodrı´guez (Hospital de Paysandu´, Montevideo).
United States: Coordinator: A. Anzueto. S.M. Aguayo (Atlanta
VA Medical Center, Decatur); R. Alagar (Allegheny General
Hospital, Pittsburgh); R.K. Albert (Denver Health Medical Cen-
ter, Denver); T.K. Aldrich (Montefiore Hospital & Medical
Center, Bronx); K. Amoosa (Medical College of Wisconsin,
Milwaukee); N. Anandarao (New York Methodist Hospital,
Brooklyn); D.C. Angus (University of Pittsburg, Pittsburgh); A.C.
Arroliga (Cleveland Clinic Foundation, Cleveland); M.F. Azrieli
(Jacobu Medical Center, Bronx); R.A. Balk (Medical Center –203
Jelke, Chicago); P.W. Bates (Maine Medical Center, Porthland);
J.F. Beamis, Jr. (Lahey Hitchcock Medical Center, Burlington);
P.E. Bellamis (Chs Dept of Medicine, Los Angeles); D.J. Bower
(Atlanta VA Medical Center, Decatur); J.P. Bradley (William
Beaumont Medical Center, El Paso); R.P. Byrd, Jr.(University of
East Tennese, Jonesboro); V.J. Cardenas, Jr.(University of Texas
Medical Branch, Galveston); L.J. Caruso (University of Florida,
Gainesville); B.R. Celli (St. Elizabeths Medical Center, Boston);
G. Clermon (University of Pittsburg, Pittsburgh); S.J. Coole (Carl
T. Hayden VA Medical Center, Phoenix); T.A. Dillard (Com-
mander MCHJ-MPU, Tacoma); L.E. Efferen (SUNY Health
Science Center, Brooklyn); E.W. Ely, Jr.(Vanderbilt Lung Trans-
plant Program Newline, Nashville); P. Factor (Michael Reese
Hospital & Medical Center, Chicago); T.M. Fitzpatrick (Walter
Reed Army Medical Ctr, Whashington); R. Fowler (Wellesley-
Central, Toronto); G.N. Giacooppe, Jr. (MCHJ-MPU, Tacoma);
K.K. Guntupalli (Texas Med Ctr - Ben Taub Gen Hospital,
Houston); J.B. Hall (University of Chicago, Chicago); M.E.
Hanley (Denver Medical Center, Denver); M.T. Haupt (Oregon
Health Science University, Portland); G.B. Hayes (St. Elizabeths
Medical Center, Boston); D.E. Heiselman (Akron General Med-
ical Center, Akron); F.C. Hiller (University of Arkansas Med
Science, Little Rock); J.D. Hinze (The Univesity of Texas Health
Science Center at San Antonio, San Antonio); R.D. Hite (Bow-
man Gray School of Medicine, Winston-Salem); R.C. Hyzy
(Henry Ford Hospital, Detroit); A. Jubran (Edward Hines VA
Hospital, Hines); C.A. Kaplan (University of Missouri Columbia,
Columbia); MS. Karetzky (Newark Beth Israel Med Ctr, New-
ark); S.A. Kurenhy (Truman Medical Center, KS); K.V. Leeper,
Jr.(Emory University School of Medicine, Atlanta); H. Levy
(University of New Mexico, Alburquerque); T. Lo (Loma Linda
University, Loma Linda); M.J. Mador (Buffalo VA Medical
Center, Bu´falo); G.P. Marelich (University of California Davis
Med Ctr, Sacramento); M.A. Matthay (University of California,
San Francisco); N.R. McIntyre (Duke University Medical Cen-
ter, Durham); S.A. Metter (Maine Medical Center, Portland);
MS. Niederman (Winthrop Univesity Hospital, Mineola); J.R.
Norman (Univesity of Mississippi Medical Center, Jackson); D.R.
Oullette (Brooke Army Medical Center, Fort Sam Houston); P.
Parsons (Denver Medical Center, Denver); R.G. Patel (VA
Medical Center, Jackson); R.C. Perkins, II (University of Texas
Health Center at Tyler, Tyler); M.E. Petrini (University of
Miississippi Medical Center, Jackson); M.R. Pinsky (University of
Pittsburg, Pittsburgh); A. Pohlman (Edward Hines VA Hospital,
Hines); K.W. Presberg (Medical College of Wisconsin, Milwau-
kee); M.P. Rocha (Carl T. Hayden VA Medical Center, Phoenix);
W. Rodrı´guez Cintron (San Juan VA Medical Center, San Juan);
M.J. Rosen(Beth Israel Medical Center, NY); T.M. Roy (James
Quillen College of Medicine, Mountain Home); G. Rudelfeld
(Harborview Medical Center, Seattle); M.J. Rumbak (University
Florida, Tampa); S.J. Ruoss (Stanford University Medical Center,
Stanford); G.A. Schmidt (University of Chicago, Chicago); R.F.
Schneider (Beth Israel Medical Center, NY); C.N. Sessler (Med-
ical College of Virginia, Richmond); C.S. Shim (Jacobi Medical
Center, Bronx); L. Smith (Rush-Presbyterian-St Lukes Medical
Center, Chicago); C. Strange (MUSC 96 Jonathan Lucas St,
Charleston); J.I. Sznajder (Michel Reese Hospital & Medical
Center, Chicago); S. Tessler (Maimonides Medical Center,
Brooklyn); V. Whyte (Loma Linda University, Loma Linda); L.
Wilkelmeyer (Loma Linda University Medical Center MC 1521,
Loma Linda); R.G. Wundering (501 Crews Wing, Memphis);
M.H. Zaman (The Brookdale Hosp Med Ctr, Brooklyn); L.H.
Zimmerman (San Francisco VA Medical Center, San Francisco).
Venezuela: Coordinator: G. DEmpaire. J. Espan˜a (Hospital
Universitario, Caracas); F. Pe´rez (Hospital de Clı´nicas, Caracas);
R. Zerpa (Hospital Militar, Caracas).
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